56.03
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Bio Techne Corp Aktie (TECH) Neueste Nachrichten
Bio-Techne (TECH) Stock Valuation After New Refeyn Bispecific Antibody Analysis Collaboration - Yahoo Finance
Bio-Techne Corp. stock outperforms competitors on strong trading day - MarketWatch
Bio-Techne (TECH) Gains 4% as Activist Investor Pushes for Strat - GuruFocus
Bio-Techne gains on report activist investor Ananym pushing for sale - Seeking Alpha
Bio-Techne stock rises as activist pushes for sale By Investing.com - Investing.com India
Activist Investor Ananym Urges Bio-Techne to Consider Selling - Bloomberg
Piper Sandler Launches Coverage on Bio-Techne (TECH), Prefers Patience on Sector Growth Drivers - Insider Monkey
Why is Techne (TECH) up 4.5% since last earnings report? - MSN
Is Bio-Techne Corporation (TECH) A Good Stock To Buy Now? - Yahoo Finance
Bio-Techne Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
TECH Initiates Coverage On Bio-Techne -- Price Target Announced at $65 - GuruFocus
Piper Sandler initiates Bio-Techne stock with neutral rating By Investing.com - Investing.com Nigeria
Piper Sandler initiates Bio-Techne stock with neutral rating - Investing.com
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
New Bispecific Antibody Characterization Workflow Might Change The Case For Investing In Bio-Techne (TECH) - Yahoo Finance
Bio-Techne Corp (TECH) Stock Analysis: Exploring a Potential 18% Upside and Strong Buy Ratings - DirectorsTalk Interviews
Bio-Techne Corporation Trade Ideas — XETR:TE1 - TradingView
ETFs Investing in Bio-Techne Corporation Stocks - TradingView
Bio-Techne Corp. stock underperforms Friday when compared to competitors - MarketWatch
Bio-Techne (TECH) Slips 2.3% as Life Sciences Sector Faces HeadwindsImbalance Zone - newsline.com
Why Is Techne (TECH) Up 4.5% Since Last Earnings Report? - Yahoo Finance
BIO-TECHNE (TECH) executive reports RSU exercise, tax withholding and corrected holdings - Stock Titan
Bio?Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization - Investing News Network
Bio-Techne and Refeyn launch workflow for antibody analysis By Investing.com - Investing.com India
Bio-Techne and Refeyn launch workflow for antibody analysis - Investing.com
New 4-hour test links charge and size in bispecific antibodies and biosimilars - Stock Titan
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
How Bio-techne Corp (TECH) Affects Rotational Strategy Timing - Stock Traders Daily
Bio-Techne Corp. stock outperforms competitors despite losses on the day - MarketWatch
Bio-Techne Corp (TECH) Stock Analysis: Exploring A Potential 18.84% Upside - DirectorsTalk Interviews
TECH Stock Price, Quote & Chart | BIO-TECHNE CORP (NASDAQ:TECH) - ChartMill
Bio-Techne (TECH) Shows Modest Upside as Shares Rebound from SupportCumulative Volume - newsline.com
Are Wall Street analysts bullish on Bio-Techne stock? - MSN
Bio-Techne (TECH) Gains 2.28% as Shares Approach Resistance ZoneRisk Parity Rebalance - newsline.com
Q1 2026 Bio-Techne Corp Earnings Call Transcript - GuruFocus
TECH Q1 2026 Earnings: EPS Misses Estimates Amid Mixed Demand SignalsPost-Earnings Drift - The Legal Advocate
Bio-Techne stock hits 52-week low at 46.04 USD By Investing.com - Investing.com Nigeria
Bio-Techne Corp (TECH) Gains Ground, Approaches Key Resistance LevelsTriple MA Cross - thelegaladvocate.com
Are Wall Street Analysts Bullish on Bio-Techne Stock? - inkl
Bio-Techne Corp (TECH) Stock Analysis: An Investor's Look At 27% Potential Upside - DirectorsTalk Interviews
Bio-Techne (TECH) Q1 2026 Earnings: EPS Misses Estimates but Shares Edge HigherAnnual Financial Report - thelegaladvocate.com
Bio-Techne Stock Is Rebounding — But One Weak Spot Could Decide the Next Move - Bez Kabli
Bio-Techne Corp (TECH) Stock Analysis: Unlocking a 41.84% Upside Potential in Healthcare Innovation - DirectorsTalk Interviews
The 5 Most Interesting Analyst Questions From Bio-Techne’s Q1 Earnings Call - Yahoo Finance
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):